

# IMMUNOTHERAPY SIDE EFFECTS IN YOUR KEYTRUDA<sup>®</sup> PATIENTS

PrKEYTRUDA<sup>®</sup> (pembrolizumab) is indicated for the treatment of adult patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. Subjects with BRAF V600 mutant melanoma may have received prior BRAF inhibitor therapy.

KEYTRUDA<sup>®</sup> as monotherapy is indicated for the first-line treatment of adult patients with metastatic NSCLC or Stage III disease where patients are not candidates for surgical resection or definitive chemoradiation, expressing PD-L1 (TPS  $\geq 1\%$ ) as determined by a validated test, with no EGFR or ALK genomic tumour aberrations. A positive association was observed between the level of PD-L1 expression and the magnitude of the treatment benefit.

# KEYTRUDA<sup>®</sup> immunotherapy side effects: WHAT TO LOOK OUT FOR

Side effects reported in clinical trials when KEYTRUDA<sup>®</sup> is given alone.



## EYES

- Change in eyesight
- Yellowing of whites of eyes
- Eye pain
- Dry eyes



## MOUTH AND HEAD

- Dry mouth
- Ulcers in mouth and/or lining of nose
- Inflammation of the mucous membranes of the mouth
- Cold sores
- Stuffy nose
- Change in sense of taste
- Dizziness or fainting
- Headaches that will not go away or unusual headache
- Feeling more thirsty than usual
- Swelling of the face
- Confusion and/or memory problems
- Seizures




## THROAT AND CHEST

- New or worse cough
- Ulcers in throat
- Voice getting deeper
- Short of breath
- Chest pain
- Rapid heartbeat
- Irregular heartbeat
- Upper respiratory tract infection



## SKIN AND HAIR

- Dry skin
- Yellowing of the skin
- Patches of skin that have lost their colour (vitiligo)
- Rash or itchy skin
- Blisters and/or sores on skin
- Peeling skin
- Ulcers in genital area
- Bleeding or bruising more easily than normal
- Sweating more than usual
- Hair falling out
- Tender lumps on skin
- Itching
- Red skin lesions
- Itchy patches of thick red skin with silvery scales (symptoms of psoriasis)
- Skin conditions resembling acne



## STOMACH AND BOWELS

- Feeling less hungry or more hungry than usual
- Nausea and/or vomiting
- Constipation
- Diarrhea
- More bowel movements than usual
- Black, tarry, sticky stools
- Stools with blood or mucus
- Severe stomach pain or tenderness
- Pain on the right side of the stomach
- Swelling of the liver or spleen



## URINE

- Changes in the amount of urine
- Changes in the colour of urine
- Need to urinate more often
- Urinary incontinence
- Difficulty urinating



## MUSCLES, JOINTS AND LEGS

- Severe or persistent muscle pain
- Severe or persistent joint pain
- Muscle problems that can cause weakness and rapid fatigue of muscles or weakness and tingling in arms and legs
- Muscle cramps or spasms
- Swelling in legs or arms
- Back pain
- Pain, numbness or tingling in arms or legs or feet or hands



## GENERAL

- Fatigue
- Dehydration
- Unusually tired or weak
- Flu-like symptoms
- Fever
- Chills
- Weight gain
- Weight loss
- Feeling colder than usual
- Swollen lymph nodes
- Low red blood cell count
- General numbness and weakness



## RELATED TO THE INFUSION

- Shortness of breath
- Itching or rash
- Dizziness or fever
- Wheezing
- Flushing
- Feeling like passing out

*It is important that **all** side effects are reported to the treating physician right away, before managing adverse reactions.*

Consult the product monograph at [www.merck.ca/static/pdf/KEYTRUDA-PM\\_E.pdf](http://www.merck.ca/static/pdf/KEYTRUDA-PM_E.pdf) for important information about:

- Relevant warnings and precautions regarding: immune-mediated adverse reactions, severe infusion-related reactions, driving and operating machinery, teratogenic risk, pregnant and nursing women, pediatric patients, patients with moderate or severe hepatic impairment and patients with severe renal impairment. Monitor liver, thyroid function and electrolytes during treatment.
- Conditions of clinical use, adverse reactions, drug interactions and dosing instruction.

The product monograph is also available by calling us at 1-800-567-2594 or by email at [medinfoCanada@merck.com](mailto:medinfoCanada@merck.com).

Should you have any questions regarding KEYTRUDA<sup>®</sup> therapy, please contact our Medical Information Centre at 1-800-567-2594.

Reference: KEYTRUDA<sup>®</sup> Product Monograph. Merck Canada Inc. March 21, 2023.



© Merck Sharp & Dohme LLC. Used under license.  
© 2018, 2023 Merck & Co., Inc., Rahway, NJ, USA  
and its affiliates. All rights reserved.



Pr **KEYTRUDA**<sup>®</sup>  
(pembrolizumab)

CA-KEY01213